NCT05999812 is a Phase 2 clinical trial of all trans Retinoic Acid in Colorectal Cancer, sponsored by University of Texas Southwestern Medical Center.

Who is sponsoring NCT05999812?

NCT05999812 is sponsored by University of Texas Southwestern Medical Center.

What drugs are being tested in NCT05999812?

Interventions in NCT05999812: all trans Retinoic Acid, Atezolizumab, Bevacizumab.

What condition does NCT05999812 study?

NCT05999812 studies Colorectal Cancer.

Is NCT05999812 still recruiting?

NCT05999812 is currently active, enrolled. Last updated 25 May 2025.

Last reviewed 2025-05-25 · How we verify

NCT05999812

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

Active, enrolled Phase 2 Last updated 25 May 2025

What this trial tests

Phase 2 trial testing all trans Retinoic Acid in Colorectal Cancer in 22 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

19 December 2023

Primary endpoint
1 October 2026

1 October 2028

Quick facts

Lead sponsor	University of Texas Southwestern Medical Center
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	19 December 2023
Primary completion	1 October 2026
Estimated completion	1 October 2028
Sites	1 location across United States

Drugs / interventions tested

all trans Retinoic Acid
Atezolizumab (atezolizumab) — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

University of Texas Southwestern Medical Center

Who can join

18 and older, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this clinical trial is to learn about the good and the bad effects of all trans retinoic acid (ATRA), atezolizumab and bevacizumab as a possible treatment for advanced colorectal patients. Participants will be treated with the following combination of these drugs: 1. ATRA will be given in a pill form to be taken twice a day at home for 7 days starting on day 1 of a cycle. 2. Atezolizumab will be given through a vein in arm or through mediport over 60-90 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW. 3. Bevacizumab will be given through a vein in arm or through mediport over 20-40 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Myeloid-Derived Suppressor Cells: Therapeutic Target for Gastrointestinal Cancers.
Arshad J, Rao A, Repp ML, Rao R, et al · · 2024 · cited 4× · PMID 38474232 · DOI 10.3390/ijms25052985
Insights into the relevance of targeting fibroblasts to control cancer.
Boeker V, Kalluri R. · · 2025 · cited 1× · PMID 41187743 · DOI 10.1016/j.xcrm.2025.102395
Synergistic Potential of Immune Checkpoint Inhibitor Combined with Neutrophil-Targeted Therapy in Cancer Immunotherapy.
Shi H, Wang J, Wang Z, Li Y, et al · · 2026 · PMID 41993094 · DOI 10.34133/research.1210

Verify or expand the search:

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other University of Texas Southwestern Medical Center trials

Trials by the same sponsor.

NCT03849963 — Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain · recruiting
NCT06917183 — Developing Strategies for Implementation and Use of the Operating Room Black Box (ORBB) · NA · not yet recruiting
NCT05145309 — Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans · Phase 2 · not yet recruiting
NCT06552000 — Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer · NA · not yet recruiting
NCT07387666 — Imaging Acetadote Metabolism in Glioblastoma · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05999812 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Texas Southwestern Medical Center
Last refreshed: 25 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05999812.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing